Company Conference Call: Reviews Phase 2 Paltusotine Results

Oct 26, 2020 at 8:00 AM EDT

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) held a conference call at 8:00 a.m. Eastern Time today discussing the results of their Phase 2 ACROBAT Edge and ACROBAT Evolve studies of paltusotine (formerly CRN00808), the company’s lead candidate for the treatment of acromegaly.

 

Company Conference Call: Review of Phase 2 Paltusotine Results

 

Webcast is currently available for 90 days

Click to view webcast archive

ACROBAT Edge Phase 2 Data Presentation

Contact


Material Selections
Country

Contact


Material Selections
Country